Precision Drug Discovery for Chronic Diseases
Steve Gardner, PhD, Co-founder and Chief Executive Officer, PrecisionLife
In the last decade, fewer than 10% of the targets investigated in drug discovery programs have led to approved drugs. The ‘blockbuster’ discovery strategy does not work well for complex, chronic diseases, leading to expensive late-stage clinical trial failures, mainly due to inability to demonstrate clinical efficacy in patients.
A new precision medicine approach, driven by high-resolution patient stratification insights, goes beyond AI drug discovery to offer a faster, cheaper, and derisked opportunity to bring to market new medicines that address significant pockets of unmet medical need, maximizing the benefits of precision medicines for both drug inventors and patients.
In this presentation, you will learn how this new approach to precision medicine is pioneering the development of better, more personalized therapy options:
- Driving novel target discovery in areas of unmet clinical need
- Identifying new opportunities for existing drugs in novel indications
- Enabling more focused clinical trials to demonstrate efficacy and reduce time to market